Literature DB >> 2997922

Genomic heterogeneity of AIDS retroviral isolates from North America and Zaire.

S Benn, R Rutledge, T Folks, J Gold, L Baker, J McCormick, P Feorino, P Piot, T Quinn, M Martin.   

Abstract

In an analysis of the genomic variation of AIDS retroviral isolates from patients living in New York, Alabama, and Zaire, restriction maps were constructed by using seven enzymes, each known to cleave the proviral DNA more than once, in conjunction with Southern blot analysis. The maps of LAV, HTLV-III, and ARV-2 as deduced from their published nucleotide sequences were included in this analysis. The results demonstrated that (i) several "signature" restriction sites were common to all isolates; (ii) with the exception of LAV and HTLV-III, the North American and European isolates were all different from one another and showed no geographical specificity; (iii) the African isolates as a group were more diverse than those from North America and Europe; and (iv) the genomic variability was concentrated within the env gene.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2997922     DOI: 10.1126/science.2997922

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  71 in total

1.  An anti-CD45RO immunotoxin eliminates T cells latently infected with HIV-1 in vitro.

Authors:  C McCoig; G Van Dyke; C S Chou; L J Picker; O Ramilo; E S Vitetta
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

2.  A mutant of human immunodeficiency virus with reduced RNA packaging and abnormal particle morphology.

Authors:  F Clavel; J M Orenstein
Journal:  J Virol       Date:  1990-10       Impact factor: 5.103

3.  The avian retrovirus env gene family: molecular analysis of host range and antigenic variants.

Authors:  C A Bova; J C Olsen; R Swanstrom
Journal:  J Virol       Date:  1988-01       Impact factor: 5.103

4.  The human immunodeficiency virus type 1-specific protein vpu is required for efficient virus maturation and release.

Authors:  T Klimkait; K Strebel; M D Hoggan; M A Martin; J M Orenstein
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

5.  Human immunodeficiency virus type 1 infection of neural xenografts.

Authors:  T A Cvetkovich; E Lazar; B M Blumberg; Y Saito; T A Eskin; R Reichman; D A Baram; C del Cerro; H E Gendelman; M del Cerro
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

6.  Induction of humoral and cell-mediated anti-human immunodeficiency virus (HIV) responses in HIV sero-negative volunteers by immunization with recombinant gp160.

Authors:  J A Kovacs; M B Vasudevachari; M Easter; R T Davey; J Falloon; M A Polis; J A Metcalf; N Salzman; M Baseler; G E Smith
Journal:  J Clin Invest       Date:  1993-08       Impact factor: 14.808

7.  Similar replication capacities of primary human immunodeficiency virus type 1 isolates derived from a wide range of clinical sources.

Authors:  W Lu; J M Andrieu
Journal:  J Virol       Date:  1992-01       Impact factor: 5.103

8.  Quasispecies and naturally occurring superinfection in feline immunodeficiency virus infection.

Authors:  M T Kyaw-Tanner; W F Robinson
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

9.  Adeno-associated virus Rep protein inhibits human immunodeficiency virus type 1 production in human cells.

Authors:  B A Antoni; A B Rabson; I L Miller; J P Trempe; N Chejanovsky; B J Carter
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

10.  Molecular cloning of a novel isolate of feline immunodeficiency virus biologically and genetically different from the original U.S. isolate.

Authors:  T Miyazawa; M Fukasawa; A Hasegawa; N Maki; K Ikuta; E Takahashi; M Hayami; T Mikami
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.